• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma

by | Apr 3, 2025 | Publications

Mol Ther. 2025 Mar 31:S1525-0016(25)00222-9. doi: 10.1016/j.ymthe.2025.03.048. Online ahead of print. ABSTRACT Bispecific antibodies (BsAb) are associated with distinct immune-related toxicities that impact morbidity and mortality. This systematic review and...

Prognostic and clinicopathological value of the controlling nutritional status score in patients with multiple myeloma: a meta-analysis

by | Apr 3, 2025 | Publications

Front Oncol. 2025 Mar 18;15:1517223. doi: 10.3389/fonc.2025.1517223. eCollection 2025. ABSTRACT BACKGROUND: The effect of the controlling nutritional status (CONUT) score on forecasting multiple myeloma (MM) prognosis is previously analyzed, whereas the results...

What Role Does MRD Play in Multiple Myeloma Treatment Decision Making?

by | Apr 1, 2025 | Uncategorized

Source: CureToday articles Dr. Surbhi Sidana discussed the topic of minimal residual disease during the CURE Educated Patient® Multiple Myeloma Summit. Read More

Depression, anxiety prevalent among adults with lymphoma, multiple myeloma

by | Apr 1, 2025 | Uncategorized

More than half of patients recently diagnosed with lymphoma or myeloma had clinically significant symptoms of anxiety or depression, according to study results.Those symptoms correlated with reduced quality of life.Oreofe O. Odejide, MD, MPH, associate professor of...

Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis

by | Mar 28, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More
« Older Entries
Next Entries »

Recent Content

  • Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes
  • (no title)
  • Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis
  • (no title)
  • Peroxiredoxins as novel indicators in multiple myeloma associated with ferroptosis and immune infiltration
  • (no title)
  • (no title)
  • (no title)
  • (no title)
  • (no title)
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT